Seres Therapeutics vs Cartesian Therapeutics
MCRB and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCRB and RNAC compare
Cartesian Therapeutics is the larger company, worth 14 times as much as Seres Therapeutics ($192M against $14.0M).
Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1193% compared with −10284% at Cartesian Therapeutics.
Seres Therapeutics scores higher on the StockData Score (6 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCRB | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $14.0M | $192M |
| Share price | $1.41 | $6.35 |
| Change, 1 year | −91.6% | −16.2% |
| Change, 5 years | −99.2% | −93.4% |
| Beta (5Y) | 0.28 | – |
| Employees | 66 | 75 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.4× (better) | 130× |
| P/B | 0.4× | – |
| FCF yield | −366% | −40.9% (better) |
| Growth | ||
| Revenue growth, 5Y average | −52.7% | −30.0% (better) |
| Net income growth (TTM) | −126% | – |
| EPS growth (TTM) | −121% | – |
| Profitability | ||
| Operating margin | −4463% (better) | −10519% |
| Net margin | −1193% (better) | −10284% |
| FCF margin | −2724% (better) | −5322% |
| Return on equity | −66.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.11 | 7.48 (better) |
| Altman Z-score | −15.93 | −4.56 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.9% | 29.3% |
| Held by insiders | 2.3% | 55.7% |
| Insider net buying, 12 months | −$10.0K (better) | −$52.9K |
| Short interest, % of float | 3.5% | 14.3% |
Go deeper
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.